Modality
Degrader
MOA
ALKi
Target
IL-23
Pathway
Wnt
Crohn'sNMOSDET
Development Pipeline
Preclinical
May 2021
→ Sep 2025
PreclinicalCurrent
NCT04528217
1,483 pts·ET
2021-05→TBD·Recruiting
NCT03108178
2,481 pts·Crohn's
2022-02→2025-09·Recruiting
3,964 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-087mo agoInterim· Crohn's
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2025-09-08 · 7mo ago
Crohn's
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04528217 | Preclinical | ET | Recruiting | 1483 | Safety |
| NCT03108178 | Preclinical | Crohn's | Recruiting | 2481 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |